April 2019

Pharma Almanack

(A Newsletter from Department of Pharmacy Practice)

SRM COLLEGE OF PHARMACY

(14thRank in NIRF 2019)

Volume 4 Issue 1 April 2019

AN OFFICIAL PUBLICATION FROM Advisory Board Members
Dr. A.Sundaram, Dean, SRMMCH & RC
Drug Information Centre, Dr.K.S.Lakshmi, Dean, SRMCP
Department of Pharmacy Practice,
SRM College of Pharmacy, Editor in-Chief: Dr.T.M.Vijayakumar
SRM Institute of Science & Technology,
Kattankulathur-603203,
Kanchipuram (Dt), Tamil Nadu.

HIGHLIGHTS OF THE ISSUE Associate Editors:
Mr. K.Karthickeyan
§ Physician’s Desk Information Mrs. S.Sarumathy
§ Updates from Clinical Trials Dr. M.Jagadeesan
§ Disease Update Ms. S.P.Ahalya
§ Orphan Drug Status Dr. A.Priyadharshini
§ DIC Activities

PHYSICIAN’S DESK INFORMATION

Dr. R.Padmanabhan MD.,DM (Neph) PPIs association with CKD
Prof & HOD, Dept. of Nephrology

SRM Medical College Hospital & Research Centre

In 1988 the first Proton Pump Inhibitor (PPI) omeprazole was launched and till date the PPIs
are amongst the most (over) prescribed drugs in clinical practice. This is due to excellent safety profile claimed in
earlier trials. Later studies which looked into PPI prescription noted that PPIs are prescribed by default with
NSAIDs, anti-diabetics and cardiovascular medications. It was found that up to 70% of prescriptions for PPIs were
inappropriate. US FDA raised a lot of safety alerts for PPI, especially in cardiac and elderly patients:
Hypomagnesemia in 2011, Clostridium Difficile associated diarrhea in 2012, Vitamin B12 deficiency in 2014 and
Acute interstitial nephritis in 2014. Besides, PPI interaction with clopidogrel was reported in 2011, and PPI
consumption was shown to be associated with increased myocardial infarction in 2015. It was in 2016; PPIs
association with CKD, progression to ESRD was reported. The Renal side effects of PPIs are less often reported and
may go unrecognized.

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

PROGRAMME ORGANIZED

SRM College of Pharmacy,
SRM Institute of Science and
Technology, Kattankulathur
established in the year 1992-
2017, celebrated its 25th year
Silver Jubilee on 12.11.2018.
Two days national conference conducted on February 7th and 8th on “Drug Discovery and
Development - A Focus on Newer Technologies”, organized by Department of Pharmaceutics, SRM College
of Pharmacy, SRMIST, Kattankulathur.

This conference provides to the
participants to have an insight on recent,
current challenges and possibilities in modeling a
new drug and breakthrough in drug development

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

UPDATES FROM RECENT CLINICAL TRIALS

§ Vitamin B12 supplements may reduce the risk of diabetes.
§ As standard TB-drug treatment are ineffective of nearly 1,30,000 of the

2.8million TB patients in India, two relatively-new and powerful drugs,
Bedaquiline, and Delamanid could benefit such patients with Drug-Resistant
(DR) TB.
§ U.S. researcher's report that for every 10 grams of fiber consumed per day, the
risk of developing heart disease may decrease 14% and the risk of dying from
heart disease may decrease 27%.
§ Methylphenidate approved for the treatment of ADHD and narcolepsy,
improves cognition, quality of life in epilepsy patients.
§ Methyldopa helps in the prevention and treatment of Type I Diabetes.
§ Use of Clarithromycin may lead to increased potential cardiac problems or
death in patients with heart disease.
§ Nasal powder formulation of Sumatriptan is best than the oral tablets in
reducing nausea.

DID YOU KNOW?

§ Our kidneys filter blood up to 300 times per day.
§ Loop diuretics are not advisable for patients those who are allergic to

Sulphonamides since it contains sulfa group in their chemical structure.
§ Marijuana is the most common drug abused in India.
§ RADAR is the abbreviated form of Research on Adverse Drug Events and

Reports
§ MONA (M- morphine O-oxygen N-nitroglycerin A-aspirin) is the abbreviation

used in the initial emergency treatment for a patient with the Acute Coronary
Syndrome.
§ The medical abbreviation of FX is Fracture.

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

DISEASE UPDATE

MARBURG VIRUS DISEASE (MVD)

MVD is formerly Marburg haemorrhagic fever, severe illness of
humans and non-human primates caused by Marburg virus, results from
prolonged exposure to mines or caves inhabited by Rousettus bat
colonies. It spreads through human-to-human transmission via direct
contact (through broken skin or mucous membranes) with the blood,
secretions, organs or other bodily fluids of infected people, and with
surfaces and materials (e.g. bedding, clothing) contaminated with these
fluids. Sexual transmission of the virus can also occur.

Incubation Period: 2 - 21 days.

Symptoms:

§ Severe headache, Malaise, High fever, Progressive and rapid debilitation

Diagnosis:

§ Antibody Enzyme-Linked Immunosorbent Assay (ELISA), Antigen Detection Tests, Serum
Neutralization Tests, Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Assay; and Virus
Isolation by Cell Culture

Treatment:

Supportive care – rehydration with oral or intravenous fluids – and treatment of specific symptoms,
improves survival. There is as yet no proven treatment available for Marburg virus disease. However, a
range of potential treatments including blood products, immune therapies and drug therapies are currently
being evaluated.

Reference:

https://www.who.int/en/news-room/fact-sheets/detail/marburg-virus-disease

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

ACHIEVEMENTS AND AWARDS

BANDARU YESWANTH RAJA and PAULIN C VARGHESE of Pharm D (Intern) received a best
poster presentation award for SUICIDAL PREVENTION on “WORLD SUICIDE PREVENTION DAY” (Sept
10, 2018) conducted by Department of Psychiatry, SRM Medical College Hospital & Research Centre,
SRMIST, Kattankulathur.

KOLLI SOWJANYA (Pharm.D
Intern) got first prize for the case
presentation (“Fluminant Hepatitis A”) in
“PHARMACY PRACTICE CASE
STUDY REVIEWS” conducted and
organized by Sri Ramachandra College of
Pharmacy, SRIHER, Porur, Chennai on
28th Feb, 2019

D. SWETHA (Vth Year Pharm.D)
and J. PRAVEEN KUMAR (IVth Year

Pharm.D) got 3rd Prize (cash price of Rs

10,000/-) in All India Pharmacy Quiz

Competition Conducted by “College of

Pharmacy, Madras Medical College”,

Chennai in the month of January 2019

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

ACHIEVEMENTS AND AWARDS

Dr.M.JAGADEESAN (Assistant Professor, Department of
Pharmacy Practice) awarded for “Best Innovative Thinker” and “Best
Poster Presentation” in Trichy SRM Medical College Hospital and
Research Centre conducted “Sixth National Workshop on Research
Methodology”, on 20th-23rd March, 2019.

JERLIN MICHELLE IMMANUEL (IInd Year Pharm.D) won IInd prize in
oral presentation for the case report entitled “Cyclosporine Induced Dyslipidemia”
in “National Conference On Pharmacovigilance Pharmacoeconomics and Outcome
Research” organized by National Coordination Centre PVPI IPC and Delhi
Pharmaceutical Sciences and Research University.

COMMUNITY ACTIVITIES

Department of Pharmacy Practice, SRM College of Pharmacy organized an Anemia Awareness, Prevention
and Treatment Camp in nearby rural areas on 3rd, June 2018.
“The term 'Pharmacoenvironmentology' seeks to deal with the environmental impact of drugs given to
humans and animals at therapeutic doses” - Syed Ziaur Rahman

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

ORPHAN DRUG STATUS

REGISTRATIONAL PHASE 3 TRIAL - FAST PATH TO MARKET

Soft tissue sarcoma (STS) is a malignant cancer cells originating in soft tissues
like muscles, tendons, fat, blood vessels, lymph and nerves. These tumors can develop
anywhere in the body but are found mostly in the chest, abdomen, arms and legs.

Incidence of STS comprises about 1% of all adult malignancies and about 15% of all pediatric
malignancies. First line sarcoma treatment options are still limited to chemotherapy. Emphasis on emerging
genomic and molecular pathway targets to combat this confounding disease.

Doxorubicin remains as a gold standard first line chemotherapy for patients with soft tissue sarcoma.
Despite modest activity and significant toxicities, no cytotoxic monotherapy has yet yielded superior overall
survival over doxorubicin for advanced STS therapy.

Aldoxorubicin is a prodrug of doxorubicin that binds to the cysteine -34 position of serum albumin
immediately after administration through an acid sensitive hydrazone linker and it is subsequently reaches the
tumor tissues; the acidic environment of the tumor cleaves the acid sensitive linker and facilitates doxorubicin
release in the targeted-tumor tissue. Because of passive accumulation within tumors, this agent may improve the
therapeutic effects of doxorubicin while minimizing systemic toxicity.

In clinical studies, there has been evidence of mitigated cardiotoxicity and less alopecia while compared
to doxorubicin. Pivotal, global phase 3 clinical trial data has supported aldoxorubicin in STS patients and did not
cause clinically significant cardiac, renal or hepatic toxicities.

STUDENT MEMBERS

§ Ms P NEELA, Pharm D (Intern)
§ Ms. PUTLURU SAI KRUTHI, Pharm D (Intern)
§ Mr. BANDARU YEWANTH RAJA, Pharm D (Intern)

Department of Pharmacy Practice, SRM College of Pharmacy

Pharma Almanack Volume 4, Issue 1

DRUG INFORMATION CENTRE

TRIALS REGISTERED IN CLINICAL TRIAL REGISTRY INDIA (CTRI)

§ Safety and Efficacy of Commonly Used Second line Oral Hypoglycemic Agents Added to Metformin
Monotherapy in Patients with Type 2 Diabetes Mellitus - A Randomized Open Label Trial (Investigators:
Dr Vijayakumar TM, Dr Kumar JS and Prof KS Lakshmi) CTRI/2018/03/012561.

§ Efficacy of Hemocare Syrup and Hemocare XT Tablets in Iron Deficiency Anemia among Women of
Reproductive Age: A Randomized, Open Label Trial (Investigators: Dr Vijayakumar TM, Dr Logaraj M
and Prof KS Lakshmi) CTRI/2018/07/014726.

§ Effectiveness of Vitamin D as a supplement with Conventional Therapy in the Treatment of Diabetic
Peripheral Neuropathy - A Randomized Controlled Clinical Trial (Investigators: Mrs S Sarumathy,
Dr Melvin George, Dr Vijayakumar TM) CTRI/2018/10/015983

§ Role of clinical pharmacist in holistic management of type II Diabetes Mellitus and patient satisfaction of
care in medical OP (Investigators: Mrs S Sarumathy, Dr Kumar JS and Dr Vijayakumar TM)
CTRI/2019/02/017516

Department of Pharmacy Practice, SRM College of Pharmacy